Modernising Subject Payments in Clinical Trials

Apr 28, 2012

Currently, the majority of clinical trial sites in the United States use paper cheques as their primary method of payment. Samuel Whitaker, Co-Founder & Chief Executive Officer at Greenphire, overviews the conventional subject payment process, identifies its shortcomings, and discusses how new electronic payment solutions are set to revolutionise subject payment in clinical trials. ...

Read More

Managing the Use of Research- Grade Kits During Clinical Trials

Apr 28, 2012

Large molecule drugs are complex, biologically synthesised pharmaceutical compounds. Owing to their complexity, large molecule drugs, such as proteins and antibodies, can be efficiently analysed using indirect immunochemical/ligand binding techniques. However, these techniques are time-consuming, creating an additional burden for bioanalytical applications. Chris Beaver, Director of Immunochemistry Services at PharmaNet, summarises the challenges of managing commercially available research grade kits during clinical trials and outsourcing to contract research organisations. ...

Read More

Feasibility, Risk Management and Clinical Trials – Art or Science?

Apr 28, 2012

With many thousands of experienced investigators globally, and innumerable completed studies, why do we need to be particularly concerned with assessing the feasibility of a clinical trial? Dr Guy Patrick MD PhD, Chief Executive Officer and Chief Medical Officer of Centrical Global Clinical Trials, explores significant pressures that have been building within the clinical trials industry to drive greater cost efficiencies and to ensure delivery of complete and quality data on time and on budget. ...

Read More

Optimising Clinical Research Site Performance through Additive Patient Enrolment

Apr 28, 2012

Twenty years ago, research sites alone would provide their total enrolment quota simply by reaching into their own database of patients. But in the last two decades, the clinical trial landscape has changed and the ripple effect has meant that sites need to go outside their practice for patients. Scott Connor, Vice President of Marketing, and Joe O’Rourke, Manager of Customer Solutions, at Acurian, consider the reasons why additive patient recruitment is no longer a nice-to-have or a rescue solution. ...

Read More

Business Partnering – The Way Forward for Cryogenics

Apr 28, 2012

The essential background of technology is being masterminded by specialists in the exacting science of cryogenics. Patrick Jackson, a qualified engineer at Vindon Scientific, explores how technology is often reliant on the expertise of one or more partners joining forces to improve overall resources. ...

Read More